Trace Sciences has been the major supplier of stable isotope targets to the nuclear medicine industry for 18 years. During this time, we looked for the right opportunity to expand and vertically integrate to better serve our customers. In carefully listening to the needs of the market it became evident that there was a necessity for a reliable, flexible and independent source for radiochemicals with proximity to all major markets within the U.S.

We listened. . .and now we are proud to announce the creation of our sister company Trace Life Sciences. located in Denton Texas. We have combined the production capability of three former entities; the world's first commercial Linear Accelerator from Advanced Molecular Imaging Inc., a CP42 Cyclotron from the University of North Texas and a second CS30 Cyclotron from Mt. Sinai Medical of Miami.

In combining the accelerator power of our assets and considering the "multi-target" capability of the Linac, Trace Life Sciences has the equivalent output of nine large cyclotrons. This will ensure the reliability of delivery and supply that has become synonymous with Trace.

Over the coming year we will be expanding power requirements and performing upgrades to accomplish this task. Since the acquisition, we have already upgraded staff and are continuing to look for the best personnel in this industry. We currently have five dedicated beam lines and target stations for Tl-201, I-123 and Cu-64. Please check our news section for further production details.